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demyelinating polyradiculoneuropathy:
a systematic review
Richard J Bright1,2,3*, Jenny Wilkinson2 and Brendon J Coventry3Abstract
Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated
progressive or relapsing disorder causing peripheral neuropathic disease of duration more than two months. Many
individuals with chronic inflammatory demyelinating polyradiculoneuropathy fail to make a long-term recovery with
current treatment regimes. The aim of this study was to prospectively review the literature to determine the
effectiveness of therapies for chronic inflammatory demyelinating polyradiculoneuropathy.
Methods: Articles published from January 1990 to December 2012 were searched for studies to treat adults with
chronic inflammatory demyelinating polyradiculoneuropathy. Peer-reviewed full-text articles published in English
were included.
Results: Nine placebo-controlled double-blinded randomised trials were reviewed to treat subjects with chronic
inflammatory demyelinating polyradiculoneuropathy exhibiting various degrees of effectiveness. The most effect
treatments were; three randomised controlled trials using intravenous immunoglobulin, a study comparing pulsed
dexamethasone and short term prednisolone and rituximab all showed promising results and were well tolerated.
Conclusion: IVIg and corticosteroids remain first line treatments for CIDP. Therapies using monoclonal antibodies,
such as Rituximab and Natalizumab offer the most promise for treatment of Chronic inflammatory demyelinating
polyradiculoneuropathy however they also need further research, as does the use of stem cell therapy for treating
Chronic inflammatory demyelinating polyradiculoneuropathy. Large randomised controlled trials and better patient
selection are required to address responsiveness of CIDP patients to conventional treatments to elucidate
mechanisms of action and future directions for therapeutic improvement.
Keywords: Chronic inflammatory demyelinating polyneuropathy, Peripheral neuropathy, Anti-myelin associated
glycoprotein, Autoimmune diseases, Treatment, Plasmapheresis, IVIg, CorticosteroidsBackground
Chronic inflammatory demyelinating polyradiculoneuro-
pathy (CIDP) is an acquired peripheral neuropathy, with
both T and B cell involvement [1]. It is the most common
peripheral autoimmune demyelinating neuropathy with a
prevalence of 1.2 to 7.7 per 100,000 worldwide, with a
slight male predominance [2]. The disease involves pro-
gressive loss of immunologic tolerance to peripheral nerve* Correspondence: richard.bright@adelaide.edu.au
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stated.components such as myelin, Schwann cell, the axon, and
motor or ganglionic neurons [3,4]. There is increasing evi-
dence that activated macrophages, T cells, and auto-
antibodies induce an immune attack against peripheral
nerve antigens [4]. Complement-fixing immunoglobulin de-
posits are localised to the myelin sheath surrounding axons
and antibodies to various glycolipids and myelin proteins
are frequently detected in subjects with CIDP and other
autoimmune neuropathies. Activated tissue macrophages
comprise the final process in the demyelinating process by
invading the lamellae causing focal damage to the myelin
sheath [2]. The resulting demyelination affects spinal roots,
proximal nerve trunks and major plexi that lead to loss oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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in clinical presentation [4,5]. The common CIDP variants
include unifocal or multifocal, pure motor, pure sensory,
sensory ataxic and pure distal forms [4]. Relatively little is
known about the pathogenesis of CIDP; however there are
many theories proposed. The occurrence of CIDP in indi-
viduals with melanoma or those who have been adminis-
tered melanoma vaccine has previously been reported,
however this finding is quite rare [6,7]. As numerous
carbohydrate epitopes are shared by melanoma cells and
myelin molecular mimicry may be a key factor in the initi-
ation of the condition. More commonly, CIDP may de-
velop after bacterial or viral infection particularly viral
hepatitis and post vaccination. It has been suggested that
viral and bacterial components have antigenic similarities
to the body’s own proteins leading to an auto-immune re-
action, or alterations in T cell function [8,9].
Currently there are no biomarkers or no clear genetic
predisposition, although approximately 20% of sufferers
have paraproteins in their serum, including anti-myelin as-
sociated glycoprotein (MAG) antibodies and elevated
cerebrospinal fluid protein levels [3]. Antibodies to GM1
ganglioside have been reported in 23% of patients with
CIDP [10], while other researchers have observed in-
creased frequency of other antibodies directed against per-
ipheral nerve antigens and in HLA antigens [11,12]. CIDP
can be described as a spectrum of diseases requiring early
recognition to enable optimum treatment management.
The disease follows a progressive, monophasic or relapsing
remitting course with clinical signs of CIDP being prox-
imal and distal weakness (usually symmetrical), sensory in-
volvement (numbness) and areflexia. Nerve conduction in
CIDP patients may exhibit prolonged distal motor latency,
slowed conduction velocity, partial conduction block and
delayed or absent F-wave [13]. Current treatments for
CIDP include immunomodulating, anti-inflammatory and
immunosuppressive drugs, and these have varying degrees
of effectiveness. The most commonly used treatments for
CIDP include; corticosteroids, intravenous immunoglobu-
lin (IVIg) and plasma exchange (PE). CIDP may improve
spontaneously without any intervention making it difficult
to judge drug efficacy in small clinical trials [14,15].
Newer immunotherapies targeting B cells, T cells,
transmigration molecules and signal transduction
pathways may have potential for treating CIDP. This
systematic review evaluates the safety and efficacy of




PubMed, Embase and The Cochrane Neuromuscular
Disease Group Trials Specialized Register were searched
from January 1990 to December 2012 inclusive forpublished articles on ‘chronic inflammatory demyelinat-
ing polyradiculoneuropathy’ and ‘treatment’. Medical
subject heading (MeSH) search terms were used to
search PubMed and a keyword search were used if
required. Keyword search terms used were; “chronic
inflammatory demyelinating polyneuropathy” or “CIDP”
or “chronic inflammatory polyneuropathy” or “autoimmune
neuropathies” combined with “drug therapy” or “treatment”
or “therapy” or “randomised control trial” or “clinical trial”.
Included in this study were double blind randomised con-
trolled trials for treating CIDP. All current and emerging
treatments for CIDP were included in the study and papers
were excluded if the diagnosis of CIDP was considered
secondary to an underlying disorder.
Study selection and participants
When journal articles did not publish the necessary data
for the analyses, attempts were made to contact the
authors. This study included adult patients of both sexes
diagnosed with CIDP according to the criteria for diagno-
sis; clinically accepted electrodiagnostic criteria, progres-
sion of weakness lasting more than eight weeks and
increased cerebrospinal fluid protein [16,17]. However
there are numerous sets of accepted criteria for the diagno-
sis of CIDP, with many variables and there is not one uni-
form set of criteria. Papers were excluded if subjects had
another systemic disease, family history of CIDP or drug or
toxin exposure known to cause CIDP. No restrictions were
set on suitable settings for involvement in this review.
Assessment of methodological quality
Studies used in the systematic review were assessed for
levels of concealment of allocation at randomisation and
internal validity to determine if any bias was present.
Quality of evidence for each study was graded from very
low to high using GRADEprofiler (http://ims.cochrane.
org/gradepro). Each paper was assessed for risk of bias,
inconsistency, indirectness, imprecision, publication bias,
large effect, plausible confounding would change the effect
and dose–response gradient. Each item was graded as
either; No- negligible, Level 1- Serious or Level 2- Very
Serious. GRADEprofiler software utilised these parameters
to report a summarised measure of the quality of evidence
from; very low, low, moderate to high (Table 1).
Statistical analysis
For the nine randomised controlled trials in this analysis,
the proportion of patients with significant improvement in
disability or the proportion that exhibited adverse effects
for the treatment were used to calculate the odds ratio and
95% confidence intervals for each study. Assumed and cor-
responding risks (95% confidence interval) were calculated
using GRADEprofiler Version 3.6 software. A summary of
findings was also created using GRADEprofiler software.
Table 1 Summary of findings and quality assessment for the qualitative analysis using grade profiler software
Randomised clinical studies to treat CIDP- summary of findings





Assumed risk Corresponding risk
With comparator With intervention
Greater than 20% reduction in mean weekly dose of corticosteroids or IVIG
Methotrexate/placebo (OR OR 1.38, 95% CI 0.5-3.87 ) 438 per 1000 518 per 1000 (280 to 751) 59 (1 study) ⊕⊕⊕⊝ Moderate [18]
Disease progression @ 32 weeks
Interferon/placebo 474 per 1000 343 per 1000 (146 to 620) 54 (1 study) ⊕⊕⊕⊝ Moderate [20]
Responders
Immunoadsorption/IVIG 500 per 1000 800 per 1000 (231 to 982) 13 (1 study) ⊕⊝⊝⊝ Very low [22]
IVIG/placebo 222 per 1000 781 per 1000 (275 to 970) 18 (1 study) ⊕⊕⊕⊝ Moderate [24]
IVIG/placebo 231 per 1000 266 per 1000 (62 to 671) 28 (1 study) ⊕⊕⊝⊝ Low [25]
IVIG/placebo 207 per 1000 542 per 1000 (344 to 728) 117 (1 study) ⊕⊕⊕⊕ High [27]
Rituximab/placebo 77 per 1000 520 per 1000 (49 to 958) 26 (1 study) ⊕⊕⊕⊝ Moderate [31]
Adverse treatment related effects
Kiovig (10% liquid immunoglobulin)/Gammagard
(5% freeze dried immunoglobulin standard)
692 per 1000 714 per 1000 (321 to 929) 27 (1 study) ⊕⊕⊕⊝ Moderate [29]
Remission at 12 months
Pulsed high-dose dexamethasone/standard
prednisolone treatment
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open-source software (http://www.cebm.brown.edu/open_-
meta) on eight of the nine randomised controlled trials.
The study by the RMC Trial Group [18] titled “Randomised
controlled trial of methotrexate for chronic inflammatory
demyelinating polyradiculoneuropathy (RMC trial): a pilot,
multicentre study”, did not fit the inclusion criteria for
meta-analysis as the outcome measure was a reduction in
the weekly dose of IVIg whereas the other studies measured
response to the therapies. To assess overall efficacy from all
the studies, we calculated odds ratio, and used a binary
random-effects model to report an overall effect, hetero-
geneity and p-value together with 95% CI [19]. Statistical
significance was declared if the p value was <0.05. Weight-
ing for each study was also reported (Figure 1).
Data extraction
Titles and abstracts selected were checked by the first
author who also determined which studies fit the inclusion
criteria. In view of the fact that different studies used
different disability scales, the primary outcome measure
was defined as the proportion of patients with a clinical
response during or after treatment. The strictest criteria to
define improvement were used in each study.Weights
Studies Percentage
Hughes et al 2010 17.5
Zinman et al 2005 6.9
Leger et al 2001 8.6
Vermeulen et al 2010 11.9
Latov et al 2010 21.4
Kuitwaard et al 2010 12.5
Dalakas et al 2009 5.4
Eftimov et al 2012 15.8
Figure 1 Meta-analysis of studies to improve recovery of CIDP versus
confidence intervals. Overall effect is shown using DerSimonian-Laird (DL) bResults
The search terms and additional searches resulted in the
identification of 540 papers from this 392 were unique
(Figure 2). After reviewing the abstracts, a further 351
citations were discarded as they did not meet the inclusion
criteria. After examining the full text of the remaining 41
articles a further 32 papers were excluded as they did not
use widely accepted case definitions or were review arti-
cles. Nine studies met the inclusion criteria for analysis
and are summarised in Table 1.
Comparison of methotrexate with placebo
RMC Trial Group [18] compared methotrexate with pla-
cebo for the treatment of CIDP. This multicenter, rando-
mised double blinded controlled trial compared oral
methotrexate (7.5 mg per week for four weeks, 10 mg for
the next four weeks and finally 15 mg for the next 32 weeks)
with placebo for CIDP patients who require either IVIg or
corticosteroids. Fifty nine patients out of 60 completed the
trial with the primary outcome being greater than 20% re-
duction in weekly dose of IVIg or corticosteroids. Fourteen
out of 27 (51.9%) treated with methotrexate and 14 out of
32 (43.8%) treated with the placebo exhibited a greater than
20% reduction in the mean weekly does of corticosteroidscontrol groups. Odds ratios are presented with 95 percent




























Did not meet 
selection criteria




Full-text articles assessed 
for eligibility 
(n=43)








Records identified through database 
searching 
(n=467)
Additional records identified 
through other sources 
(n=216)




Figure 2 Flow diagram showing selection of articles for review.
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no serious treatment related effects in either group to
methotrexate. Oral methotrexate did not show any signifi-
cant benefit, however limitations in study design and high
response rate in the placebo group may have been due to a
higher than necessary dose of IVIg or corticosteroids that
had been administered prior to the starting the study.
Interferon versus placebo
A clinical trial comparing interferon (IFNβ 1α) with pla-
cebo followed by IVIg was undertaken by Hughes et al.
[20]. Forty five patients received either IFNβ 1α (30 μg or
60 μg intramuscular) once or twice a week plus placebo
and 22 patients received placebo twice per week. Partici-
pants also received their stable IVIg regimen (2 to 5 doses
per week, n = 31 received ≤ 0.95 g/kg IVIg and n = 32
received >0.95 g/kg IVIg) from week 1 through to week
16, and subjects who deteriorated post week 16 were
re-administered IVIg until stable. The primary outcome
was the total IVIg administered from week 16 to week 32,
and secondary outcome was time to disease progression.
There was no difference in the total IVIg administered after
week 16 in both groups (p = 0.75), however the authors
suggested IFNβ 1α reduced the total dose of IVIg in
patients who required higher dose (>0.95 g/kg/month). The
secondary outcome of a ≥ 2 point decrease in medical
research council (MRC) sum score [21] and a 1 pointincrease in the overall disability status scale (ODSS), was
not significant between the treatment and placebo groups
(p = 0.67). Twelve out of 35 (34.3%) subjects given IFNβ 1α
and 9 out of 19 (47.4%) in the placebo group exhibited
disease progression from the time of IVIg withdrawal at
week sixteen (OR 0.58, 95% CI 0.19-1.81, p = 0.67)
(Figure 1). Adverse effects were observed more commonly
in the IFNβ 1α arm, which included flu-like symptoms,
headache and fatigue. The dropout rate (>20%) resulted in
the study being underpowered for the detection of smaller
clinically meaningful differences, and the studies were
subsequently classified as a class II. There was no effect on
the primary and secondary outcome measures on the four
dose regimes of IFNβ 1α therapy combined with IVIg.
Excorim staphylococcal protein immunoadsorption
versus IVIg
A pilot study commenced at the Toronto General Hospital
from 2003 to 2004 to evaluate the efficacy and safety of im-
munoglobulin removal by Excorim Immunoadsorption
(IA) [22]. Twenty treatment naïve (other than prednisone)
subjects with probable CIDP were randomly assigned to IA
or IVIg (1 g/kg/day × 2 days). The drop-out rate over the
duration of the trial was 35% due to illness and two deaths
were reported, however they were unrelated to the treat-
ment. Patients assigned to IA received three treatments
over a 7 day period, with a total of 3 plasma volumes
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nerve conduction parameters, grip strength and the
Toronto Clinical Neuropathy Score (TCNS) [23] measured
post initiation of treatment at 2 and 6 months. Two months
after commencement of the study, 4 out 5 (80%) treated
with IA and 4 out of 8 (50%) on the IVIg arm responded
well to the treatment (OR 4.0, 95% CI 0.30-53.47) (Table 1
and Figure 1). At 6 months after treatment commencement
100% (4/4) of the IA arm and 50% (3/6) of the IVIg arm
continued to exhibit substantial clinical response (p = 0.2).
Both treatments were well tolerated, with minimal adverse
effects. The study demonstrated the efficacy and safety of
IA, however it was not sufficiently powered to detect
significant difference between the two treatments. An ap-
propriately powered randomised double-blind controlled
clinical trial with stratification for disease duration would
be required to determine the usefulness of IA therapy.
Efficacy of IVIg therapy for CIDP
Three randomised controlled clinical trials studying the
efficacy and safety of IVIg were identified and included in
the review (Table 1). Leger et al. [24] undertook a double-
blind, placebo controlled crossover study of nineteen
subjects with demyelinating neuropathy and persistent
nerve conduction block. Participants were randomly
assigned to receive either IVIg (500 mg/kg/day × 5 days) or
placebo (1% human albumin) once a month for 3 months.
After 3 months participants had a double blind clinical as-
sessment. Responders remained on the same treatment and
non-responders switched to the alternative study drug
for the remaining three months. The outcome measures
were MRC score, nerve conduction and self-evaluation
parameters. Follow up evaluation was performed at 4
and 7 months. Eighteen of the 20 subjects were eligible
for analysis, 9 in each arm of the study. At four months
77.8% (7/9) of participants who received IVIg first and
22.2% (2/9) who received the placebo responded well to
the self-evaluation parameters (OR 12.25, 95% CI 1.33-
113.06, p = 0.03). No serious treatment related effects
were noted in this study. Although the trial was small
and not powered significantly, it did show IVIg was
effective treating the symptoms of in CIDP.
Vermeulen and colleagues [25] undertook a double-
blind placebo controlled multicentered trial investigating
the efficacy of IVIg. Participants were randomised to
receive either IVIg (n = 15) or placebo (n = 13) (Table 1).
The primary outcome measure was a one point decease
on the modified Rankin scale [26]. Weakness of three arm
and three leg muscles on both sides of the body were also
assessed using the MRC sixty point scales. The assess-
ments were done at day 1, then again between day 16 and
21 and also after the completion of the trial. Four of fifteen
(26.7%) and 3 of 13 (23.6%) subjects who received IVIg
and placebo respectively improved by one point on theRankin scale (OR 1.21, 95% CI 0.21-6.80). No significant
difference was observed between the treatment and
placebo groups possibly due to patient selection, treatment
allocation and type II error may be a consideration due to
the small sample size. There may be other factors in the
placebo (20% albumin solution) that may have contributed
to the clinical response seen in the placebo group, such as
immunoglobulins other than IgG and proteins including
albumin. It was concluded that better patient selection,
selection of an appropriate placebo and larger participant
number to statically power the study would be required.
Further investigation would also be warranted to iden-
tify factors within the albumin fraction that may be
beneficial to CIDP patients. The study did not mention
adverse treatment related effects. Latov et al. [27]
undertook a study investigating the timing, course and
clinical characteristics of IVIg treatment for CIDP. One
hundred and seventeen subjects with CIDP were ran-
domly assigned to IVIg (Gamunex, n = 59) or placebo
(0.1% albumin, n = 58) [27]. Participants receiving the
IVIg, were initially administered a loading dose of 2 g/kg
IVIg for 2 to 4 days followed by a maintenance dose of
1 g/kg IVIg /3 weeks for a maximum of 24 weeks. The
main outcome measure was an improvement of at least
one point on the INCAT disability score [28] at week six
and maintained through to week twenty four. Fifty four
percent (32/59) treated with IVIg were clinical responders
versus 20.7% (12/58) of subjects who received the placebo
(OR 4.54, 95% CI 2.01-10.28, p < 0.001).
These observations suggest that a loading dose
followed by three weekly maintenance doses of IVIg may
be required to achieve a maximum therapeutic response.
No serious adverse effects were reported. No bias was
detected in this study.
Comparison of two different preparations of IVIg
The primary objective of a study reported by Kuitwaard
et al. [29] was to compare the efficacy and safety of two
different brands of IVIg for the treatment of CIDP. Twenty
seven subjects were randomised to receive either the stand-
ard 5% IVIg (Gammagard S/D freeze dried IVIg, n = 13) or
the new 10% liquid IVIg (Kiovig, n = 14). The primary out-
come measure was a change in overall disability sum score
(ODSS), and the secondary outcome measure was the
MRC sum score. There was no significant difference for all
measures of outcome between the two treatments. ODSS
difference from analysis of covariance with adjustment for
baseline values was 0.004 (Gammagard minus Kiovig) (95%
CI −0.4-0.4 p = 0.98) and MRC sum score was −0.58 (95%
CI −1.9-0.7 p = 0.37). The number of subjects who reported
adverse effects was similar in groups, 71% in the Gamma-
gard group and 69.2% in the Kiovig group (p = 0.86, OR
1.11, 95% CI 0.21-5.80). This study demonstrated similar ef-
ficacy and adverse effects between Gammagard and Kiovig.
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not possible to blind the nursing staff as dosages of the two
IVIg preparations (Gammagard 5% IVIg and Kiovig 10%
IVIg) had to be the same.
Comparison of Rituximab with placebo
Rituximab is a humanised murine monoclonal antibody
directed against CD20, a cell surface protein found on B
lymphocytes the precursors of antibody producing
plasma cells, thus depleting circulatory B cells. The im-
munotherapy drug has showed promising results in treating
autoimmune diseases and has been approved for the treat-
ment of rheumatoid arthritis [30]. A double-blind placebo
controlled trial was conducted to determine the efficacy
of rituximab in patients with demyelinating neuropathy
[31]. Twenty six subjects with CIDP were randomised to
375 mg/m2 of rituximab (n = 13) or placebo (n = 13)
(Table 1). Rituximab was administered in four, weekly
cycles intravenously and the placebo consisted of an iso-
tonic saline solution. The primary outcome measure was
an improvement of ≥ 1 INCAT disability score at baseline
and 8 months. Intention to treat analysis was not significant
(p = 0.96) due to one subject treated with rituximab had a
normal (0) INCAT disability score at the beginning of the
trial. When participants were removed from the analysis
because they did not improve with the study period the
remaining data showed a significant improvement over the
placebo (p = 0.036). Four out of thirteen (30%) of subjects
treated with rituximab improved by ≥ 1 INCAT disability
score compared to 0% in the placebo group (OR 12.79, 95%
CI 0.61-266.66). No significant changes in the MRC score
or nerve conduction studies were reported in the rituximab
group. The most common side effects reported in the ritux-
imab treated subjects were mild temperature increases and
chills. Although the sample size was small, rituximab
improved the clinical response in patients with treatment
resistant demyelinating neuropathy.
Pulsed dexamethasone versus short term standard
prednisolone
A multicentered retrospective randomised controlled trial
compared pulsed dexamethasone prednisolone to treat
CIDP [32]. Forty newly diagnosed subjects with CIDP
were randomised to receive pulsed courses of oral 40 mg
per day dexamethasone for six months (n = 24) or 60 mg
prednisolone daily for eight months (n = 16) (Table 1).
One participant from the prednisolone arm was lost
during follow-up. Based on improvement of the INCAT
disability scale and RMI [26,33] the treating neurologists
were asked to score treatment effect, remission, stable
disease and non-responders. Ten of 24 (41.7%) subjects
treated with pulsed dexamethasone and 6 of 16 (37.5%) on
daily prednisolone were in remission at follow-up (OR
1.19, 95% CI 0.33-4.36). The median interval from thebeginning of the remission to relapse was 11 months for
prednisolone and 17.5 months for pulsed dexamethasone.
Adverse treatment related events were low in both groups.
There was no difference between treating subjects with
either pulsed dexamethasone or standard daily prednisol-
one, however long-term remission was possible in 25%
of sufferers with CIDP after only one or two courses of
monthly dexamethasone compared with eight months of
daily prednisolone. The authors failed to analyse the treat-
ment related responses for statistical significance due to
heterogeneity. At follow-up many of the non-responders
were determined to have been misdiagnosed. Randomisa-
tion was achieved with a random number generator, how-
ever the study failed to conceal allocation and there was
an absence of blinding [34].
Discussion
The purpose of this systematic review was to evaluate
recent randomised clinical trials to determine the efficacy
and safety of current therapies in the recovery of CIDP.
Overall all treatment modalities for CIDP favoured a posi-
tive response (OR 2.10, 95% CI 0.96-4.61, p = 0.05)
(Figure 1). Two important observations arose from this
review; firstly, there is a need to use better objective scales
to measure disability and assess long-term outcomes and
responses to treatments. Secondly there is a need to be able
to identify and omit subjects with stable or inactive disease,
as they would be naturally less likely to respond to new or
novel treatments. Recent research illustrated that up to 40%
of subjects with CIDP were in remission or cured, but in-
cluded in clinical trials, however CIDP patients can exhibit
spontaneously improvement. This may explain why there
was a high placebo response rate observed in some clinical
trials [15,27]. Using a reliable scale such as CIDP Disease
Activity Status (CDAS) in patient recruitment for clinical
trials would provide more meaningful data with fewer pa-
tients. Constructing better powered larger studies would
also assist in demonstrating potentially important small dif-
ferences and in data interpretation. The data from the sys-
tematic review identified, that IVIg appeared to provide an
effective treatment option for subjects with active CIDP,
particularly evident in the studies by Zinman et al. [22],
Latov et al. [27] and Leger et al. [24]. Further studies are
necessary to investigate plasma factors other than im-
munoglobulins in IVIg, which may result in an increase
in clinical response rates in trials using albumin as pla-
cebo. Replacing albumin with isotonic saline would be a
better choice for the placebo. As discussed previously,
this phenomenon was seen in an IVIg versus placebo
trial undertaken by Vermeulen et al. [25], however the
high clinical response rate observed in the control arm
may also be due to patients being incorrectly diagnosed
or possibly spontaneous recovery from the disorder. Ri-
tuximab showed promising results [31], however larger
Bright et al. BMC Neurology 2014, 14:26 Page 8 of 9
http://www.biomedcentral.com/1471-2377/14/26randomised clinical trials with long-term follow up
would be required. Heterogeneity was moderate be-
tween the eight randomised controlled studies included
(Tau2 = 0.58, Q = 14.05, I2 = 50% and p = 0.05) and due
to the variability of the disease the binary random effect
model was used in this study. This was to be expected
as the treatments varied considerably and it was not the
purpose of this review to combine studies. The system-
atic review did not include plasma exchange therapy,
however two double crossover trials identified did not
fit inclusion criteria and had been previously reported
[35]. The two clinical trials using plasma exchange for
the treatment of CIDP demonstrated a significantly better
outcome in the treatment groups [36,37]. Due to the rarity
and numerous variants of CIDP, limited large clinical trials
have been undertaken. Clinical trials with similar auto-
immune inflammatory diseases such as Guillain–Barré
syndrome, multiple sclerosis and Crohn's disease may also
provide some guidance in treatment options for those suf-
fering from CIDP. Two compounds, Kv1.3 and KCa3.1
(voltage-gated potassium channel and calcium activated
potassium channel inhibitors respectively) have shown
promising results in animal studies for the treatment of
autoimmune diseases such as multiple sclerosis, psoriasis
and type-one diabetes may also benefit subjects with CIDP
[38,39]. Currently a clinical trial is underway to observe
whether alpha lipoic acid, an antioxidant with anti-
inflammatory properties may prove effective to treat CIDP
symptoms (ClinicalTrials.gov Identifier: NCT00962429).
Hematopoietic stem cell transplantation for treating CIDP
is also showing some promise [40], with a clinical trial ac-
tively recruiting participants (ClinicalTrials.gov Identifier:
NCT00278629). With the development of antigen arrays,
customised DNA vaccines may have potential to cure
CIDP and other autoimmune disorders by tolerizing
against an aberrant immune response observed in subjects
with CIDP.Conclusion
This systematic review demonstrated that IVIg and corti-
costeroids still provide the most effective first line treat-
ment options for patients with active CIDP. The review
also revealed there is a pressing need for further basic re-
search into the pathogenesis of CIDP to ultimately develop
new therapies for more effective treatment. Larger rando-
mised controlled studies are required to define the validity
and efficacy of treatments such as stem cell transplant-
ation and immune-modulating agents. Better definition of
CIDP is also required due to wide spectrum and the vari-
ability of clinical presentations of CIDP, together with the
use of a valid disability scale such as CDAS, to ultimately
lead to better subject selection for long-term studies of
CIDP therapies.Abbreviations
IVIg: Intravenous immunoglobulin; CIDP: Chronic inflammatory
demyelinating polyradiculoneuropathy; MAG: Anti-myelin associated
glycoprotein; PE: Plasma exchange; MRC: Medical research council;
ODSS: Overall disability sum score; CDAS: CIDP Disease activity status.
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